NEW YORK, Feb. 02, 2017 -- TransPerfect, the world’s largest privately held provider of language services and translation-related technology solutions, today announced the launch of DaVita’s participant resource site in Spanish.
DaVita Clinical Research (DCR), a contract research organization and a wholly owned subsidiary of DaVita Inc., uses their extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment, and completion of retrospective, prospective, and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies over the last 30 years.
DaVita used TransPerfect’s GlobalLink OneLink proxy-based website localization technology to configure, deploy, and test their new Spanish participant site at www.isupportresearch.com. OneLink was the preferred solution due to its simple implementation, powerful capabilities, and automated change detection. The result was a fully translated website with virtually no IT involvement.
“As our business grew to encompass Spanish-speaking staff, extending that capability to our community and increasing inclusion was important,” said Amy Young, General Manager of DaVita Clinical Research. “Transperfect’s OneLink technology is a great way for us to virtually open our doors to a broader portion of our community.”
Liz Elting, Co-CEO at TransPerfect remarked, “DaVita Clinical Research’s unwavering commitment to innovation in healthcare that improves outcomes is truly commendable. We’re extremely proud to call them a partner, and we look forward to providing their Spanish-speaking participants with an enhanced online experience.”
Phil Shawe, Co-CEO at TransPerfect added, “Digital tools are playing an increasingly crucial role in clinical research and in the healthcare industry as a whole. By expanding language access for their website, DaVita has opened up their valuable research to a whole new set of candidates and options.”
About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment, and completion of retrospective, prospective and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR’s Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, and Real-World Healthcare Data, are focused on providing world-class research in both complex/specialty populations and therapeutic areas and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.
About TransPerfect
With annual revenues of more than $540 million, TransPerfect is the world's largest privately held provider of language services and technology solutions. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 3,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.
Contact: Ryan Simper +1 212.689.5555 [email protected]


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Instagram Outage Disrupts Thousands of U.S. Users
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Washington Post Publisher Will Lewis Steps Down After Layoffs
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



